TITLE

FDA clears PressureWire Certus for further indication

PUB. DATE
November 2008
SOURCE
Cardiology Today;Nov2008, Vol. 11 Issue 11, p38
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article focuses on the new regulatory clearance given to Radi's PressureWire Certus by the U.S. Food and Drug Administration (FDA). It is mentioned that PressureWire Certus was cleared for use in the coronary and peripheral blood vessels and can be used to determine pressure measurements across heart valves and into various heart chambers. Ted Feldman of Evanston Hospital's cardiology division in Evanston, Illinois, said that his personal use of the product has made a real difference for patient management.
ACCESSION #
35639368

 

Related Articles

  • Edwards Gets Nod from Panel; Talk of Stroke Threat Cools Shares. Reed, Vita // Orange County Business Journal;7/25/2011, Vol. 34 Issue 30, p10 

    The article reports on the decision of a U.S. Food and Drug Administration (FDA) panel over Edwards Sapien valve from Edwards Lifesciences Corp. for patients with severe aortic valve.

  • New Option May Help Patients with Pulmonary Valve Disease.  // Heart Advisor;Sep2013, Vol. 16 Issue 9, p5 

    The article reports that the Melody Transcatheter Pulmonary Valve from Medtronic Inc. which has been approved by the U.S. Food and Drug Administration can be helpful for adults with a congenital heart condition that affects the health of the pulmonary valve.

  • Mixing diet drugs calls for caution.  // FDA Consumer;Sep/Oct97, Vol. 31 Issue 6, p3 

    Scrutinizes US Food and Drug Administration's advise on doctors to monitor heart valve disease in women on taking obesity drugs, fenfluramine and phentermine, as therapy. Indications of the drugs; Responsibilities of health professionals in giving the therapy to the patients.

  • Cardiac valvulopathy associated with exposure to... Bowen, R.; Glicklich, A. // MMWR: Morbidity & Mortality Weekly Report;11/14/1997, Vol. 46 Issue 45, p1061 

    Reports the summary of data gathered by the US Food and Drug Administration (FDA) about the increased cases of fenfluramine or dexfenfluramine-associated valvulopathy. Decision to request voluntary withdrawal of these drugs from the market; Interim public health recommendations for persons...

  • Less Leakage With New Heart Valve. Voelker, Rebecca // JAMA: Journal of the American Medical Association;8/4/2015, Vol. 314 Issue 5, p443 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the SAPIEN 3 Transcatheter Heart Valve for patients with aortic valve stenosis after it was redesigned to minimize blood leakage.

  • Additional Isights Into Pergolide-Associated Valvular Heart Disease. Lanier, William L. // Mayo Clinic Proceedings;Jun2003, Vol. 78 Issue 6, p684 

    Editorial. Focuses on pergolide-associated valvular heart disease (PAVHD). Risk of PAVHD, according to the drug company Eli Lilly & Co.; Collaboration between the 'Mayo Clinic Proceedings' and U.S. Food and Drug Administration; Possible errors in assessing the incidence of PAVHD.

  • The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Flowers, Charlene M.; Racoosin, Judith A.; Lu, Susan L.; Beitz, Julie G. // Mayo Clinic Proceedings;Jun2003, Vol. 78 Issue 6, p730 

    Discusses the U.S. Food and Drug Administration's (FDA) registry of patients with pergolide-associated valvular heart disease. Summary of 12 cases in the FDA database; Comparison with three cases reported in the 'Mayo Clinic Proceedings'; Association between fibrotic changes and ergot derivatives.

  • FDA APPROVES PROMUS EVEROLIMUS-ELUTING CORONARY STENT.  // Biotech Equipment Update;Aug2008, Vol. 16 Issue 8, p8 

    The article reports on the approval given by the U.S. Food and Drug Administration to Natick, Massachusetts-based Boston Scientific Corp.'s PROMUS Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease. Ted Feldman, Director of the Cardiac Catheterization...

  • Decellularized heart valve from CryoLife gains FDA-clearance. Yoffee, Lynn // Medical Device Daily;2/11/2008, Vol. 12 Issue 28, p1 

    The article reports that CryoLife's SynerGraft pulmonary and decellularized human heart valve has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). D. Ashley Lee, CFO and COO of CryoLife, tells the significance of the products approval to people with diseased pulmonic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics